Repositioning Candidate Details
| Candidate ID: | R1455 |
| Source ID: | DB12589 |
| Source Type: | investigational |
| Compound Type: | biotech |
| Compound Name: | Dacetuzumab |
| Synonyms: | Dacetuzumab |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | Dacetuzumab has been used in trials studying the treatment of Multiple Myeloma, Non-Hodgkin Lymphoma, Leukemia, Lymphocytic, Chronic, and Lymphoma, Large B-Cell, Diffuse. It is a humanized anti-CD40 antibody and induces cytotoxicity in human multiple myeloma cells. |
| CAS Number: | 880486-59-9 |
| Molecular Weight: | |
| DrugBank Indication: | Investigated for use/treatment in lymphoma (non-hodgkin's) and multiple myeloma. |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | -- |
| Targets: | Tumor necrosis factor receptor superfamily member 5 |
| Inclusion Criteria: | Target associated |
